Meet PSI at MSToronto 2026!
PSI CRO is attending MSToronto 2026 to discuss how sponsors can maintain enrollment predictability, operational visibility, and data quality in increasingly complex multiple sclerosis trials.
MS development programs face growing pressure around recruitment timelines, evolving endpoint strategies, and operational consistency across global sites. PSI brings more than 25 years of CNS trial experience spanning MS, Parkinson’s disease, Alzheimer’s disease, stroke, and spasticity studies. Notably, 75% of MS drug approvals over the past five years were based on data generated with PSI support.
Sponsors attending MSToronto 2026 can meet with the PSI team to discuss enrollment planning, global site strategy, AI-enabled site identification through SYNETIC™, and operational approaches that support predictable delivery in Phase 2–3 neurology trials.
Attending team members:
- Scott Clark
Senior Director, Business Development - Adam Couture
Associate Director, Business Development
Related resources:
Case Study: Speeding time-to-market for a novel MS therapy
Webinar: Agentic AI in Clinical Trials — Swiss Biotech Day Panel
White Paper: The operational reality of agentic AI in phase 2-3 trials
